Ozempic and Gastroparesis: Understanding the FDA Warning in Context

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Medication Safety

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. The FDA has issued a warning about this potential risk, and understanding the evidence is essential. The tradition of rigorous medication safety evaluation has long guided public health communication, and this page examines the current research and regulatory context surrounding Ozempic and gastroparesis.

Understanding Gastroparesis and Ozempic’s Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, with symptom assessment and exclusion of other causes. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. The prescribing information for Ozempic documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo in placebo-controlled trials: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported with Ozempic at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as a separate adverse reaction in these data, the symptoms overlap significantly with those of delayed gastric emptying, a known pharmacodynamic effect of GLP-1 agonists.

Evidence Linking Ozempic to Gastroparesis

Mechanistically, Ozempic slows gastric motility by activating GLP-1 receptors on vagal afferent neurons and enteric neurons, reducing antral contractions and increasing pyloric tone. This can lead to prolonged gastric retention, which in susceptible individuals may progress to clinically significant gastroparesis. The timeline between exposure and documented harm is variable; gastrointestinal symptoms often emerge during dose escalation, as noted in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, cases of gastroparesis may develop after weeks to months of treatment, and symptoms can persist after drug discontinuation in some patients. Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a point of concern. The prescribing information includes warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically warn about gastroparesis. Instead, it groups gastrointestinal adverse reactions under general categories. This may lead to under-recognition of gastroparesis as a potential complication, particularly in patients with pre-existing gastrointestinal conditions or those taking other medications that slow gastric emptying. For affected patients, causation considerations are complex. Gastroparesis can have multiple etiologies, including diabetes itself, which is the primary indication for Ozempic. Diabetic gastroparesis is a known complication of long-standing diabetes, making it challenging to attribute symptoms solely to Ozempic. However, the temporal relationship—symptom onset after starting Ozempic, especially during dose escalation—supports a drug-induced component. Patients who develop severe or persistent gastrointestinal symptoms should be evaluated for gastroparesis, and discontinuation of Ozempic may be considered if symptoms are disabling or if alternative causes are excluded. The timeline between exposure and documented harm is not precisely defined in clinical trials, but the prescribing information indicates that gastrointestinal adverse reactions are most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that early monitoring is critical. Patients who experience nausea, vomiting, or abdominal pain that does not resolve with dose adjustment may be at higher risk for developing gastroparesis. Long-term data on the incidence of gastroparesis with Ozempic are limited, as the condition is not routinely captured as a distinct adverse event in clinical trials.

Risk Context and Clinical Implications

In summary, while Ozempic does not have a specific label warning for gastroparesis, its pharmacological action of slowing gastric emptying, combined with the high frequency of gastrointestinal adverse reactions, provides a plausible mechanistic link. The evidence from clinical trials shows a dose-dependent increase in gastrointestinal symptoms, but gastroparesis as a formal diagnosis is not separately reported. Patients and clinicians should be aware of this potential risk, particularly during dose escalation, and consider gastroparesis in the differential diagnosis of persistent gastrointestinal symptoms. Further research is needed to clarify the incidence, risk factors, and long-term outcomes of Ozempic-associated gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, symptom assessment, and exclusion of other causes.

Does Ozempic cause gastroparesis?

While Ozempic does not have a specific label warning for gastroparesis, its mechanism of slowing gastric emptying and the high frequency of gastrointestinal adverse reactions provide a plausible link. Clinical trials show dose-dependent gastrointestinal symptoms, but gastroparesis as a formal diagnosis is not separately reported. Patients should be monitored for persistent symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.